.jpg "LivaNova PLC (NASDAQ: LIVN)")
In a report released today, Michael Matson from Needham maintained a Buy rating on LivaNova PLC (LIVN), with a price target of $100. The company’s shares opened today at $69.59, close to its 52-week low of $68.30.
According to TipRanks.com, Matson is a 5-star analyst with an average return of 12.2% and a 66.8% success rate. Matson covers the Healthcare sector, focusing on stocks such as Boston Scientific Corp, Cardiovascular Systems, and Zimmer Biomet Holdings.
LivaNova PLC has an analyst consensus of Moderate Buy, with a price target consensus of $109.60, implying a 57.5% upside from current levels. In a report issued on March 29, Piper Jaffray also maintained a Buy rating on the stock with a $120 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $131.54 and a one-year low of $68.30. Currently, LivaNova PLC has an average volume of 617.7K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
LivaNova Plc is a global medical technology company, which engages in the development and delivery of important therapeutic solutions for the benefit of patients, healthcare professionals and healthcare systems. It operates through the following segments: Cardiovascular, Neuromodulation, and Others.
